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Georgia Southern Monitors for Adverse Events Post Marketing
Approval of Drugs
December 2, 2015
Regardless of the efforts of a pharmaceutical company and of the US Food and Drug
Administration (FDA) to identify harmful side effects prior to regulatory approval of a new
drug, it is not possible to identify all such serious adverse events (SAE’s). There are many
reasons for this; chief among them is the fact that the number of patients in clinical
development programs of new drugs to prove efficacy are inadequate to detect rare SAE’s.
It is therefore in a company’s best interest to develop a post marketing risk based
monitoring plan (RBMP) of their drug as it is made available to patients through physician
prescriptions after regulatory approval.
This manuscript provides information to those developing monitoring plans for SAE’s
following regulatory approval of a new drug. In addition, we (1) illustrate how many patients
would need to be treated in order to have high confidence of seeing at least 1 pre-specified
SAE, (2) show that absence of proof of a SAE is not proof of absence of that SAE, and (3)
identify statistical methodology that could be used for formal statistical monitoring of SAE’s.
“Monitoring for Adverse Events Post Marketing Approval of Drugs,” is published in the International Journal of
Allergy Medications.
Dr. Karl E. Peace, professor of biostatistics at JPHCOPH and Georgia Cancer Coalition Distinguished Cancer
Scholar was the lead author and Dr. Macaulay Okwuokenye, alumni of the Doctor of Public Health in Biostatistics
program at the Jiann-Ping Hsu College of Public Health (JPHCOPH) at Georgia Southern University was the co-
author.
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